

ASX ANNOUNCEMENT

UPDATE ON JAPANESE SALES

SYDNEY, Thursday, 26 MAY 2016: Cellmid Limited (ASX:CDY) refers to its announcements on the 9 July 2015 and 23 February 2016 and pleased to advise on record results for the month of April 2016 by its Japanese subsidiary, Advangen Inc., with net sales of JPY46,900,760 (A\$558,165).

The Company will provide further update to the market in due course.

End

Contact:

Maria Halasz, CEO,

+612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Through its Advangen business, Cellmid sells its FGF5 inhibitor hair growth products in Australia and Japan, and expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.